Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…
A judge has stayed a class action on behalf of 6,000 women allegedly injured by defective pelvic mesh devices after Astora Women’s Health filed for bankruptcy in the United States, but questioned how the company had suddenly come to have no assets.
Medibank’s woes worsened Wednesday as the insurer revealed data for all 4 million of its current and former customers had been accessed during a cyberattack after initially reporting no customer data had been exposed.
A class action against Bayer over its allegedly defective Essure contraceptive devices has admonished the drug manufacturer’s bid to shield emails considered privileged in similar US litigation, arguing “thoughts and prayers” are needed to sustain the claim.
The fallout from a cyberattack against Medibank continues, with the health insurer revealing sensitive claims data was accessed for customers of its main Medibank branch.
A criminal has accessed sensitive Medibank customer data, including claims information, following a recent cyberattack.
French drug giant Sanofi has appealed a decision giving American biopharmaceutical company Amgen the go-ahead for its patents for a cholesterol-lowering antibody that could be used to treat heart disease, diabetes, stroke and Alzheimer’s.
Medibank has become the latest company to fall prey to a cyberattack, but the health insurer says so far there’s no indication customer data has been compromised.
US medical device manufacturer Boston Scientific has withdrawn a controversial gag clause from of its $105 million deal to settle a class action by women allegedly injured by pelvic mesh devices after a judge raised concerns about its legality.
A judge has savaged Shine Lawyers over its failure to present a signed settlement agreement to the court a month after Johnson & Johnson Medical and unit Ethicon agreed to pay $300 million to settle two pelvic mesh class actions, ordering the firm to explain on the record what steps have been taken to finalise the settlement.